Arbutus Biopharma Corporation

NasdaqGS:ABUS Rapport sur les actions

Capitalisation boursière : US$847.6m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Arbutus Biopharma Croissance future

Future contrôle des critères 2/6

Arbutus Biopharma devrait augmenter ses bénéfices et ses revenus de 10.8% et de 34% par an respectivement, tandis que le BPA devrait croître de croître de 14.3% par an.

Informations clés

10.9%

Taux de croissance des bénéfices

14.3%

Taux de croissance du BPA

Biotechs croissance des bénéfices29.6%
Taux de croissance des recettes33.9%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour05 Sep 2024

Mises à jour récentes de la croissance future

Recent updates

Arbutus Biopharma's IP Legal Wins And Clinical Trials - A Strong Buy Opportunity

Jul 05

Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up

May 23
Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shares Climb 29% But Its Business Is Yet to Catch Up

Moderna Investors Should Beware Patent-Dispute Fallout

Apr 23

Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains

Apr 10

Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Feb 10
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 03
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Nov 09
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

Oct 24
Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Apr 26
We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

Nov 11
Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Oct 28
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'

Sep 12

Arbutus stock rises on US patent linked to hepatitis B therapy AB-729

Aug 30

Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Aug 06
Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial

Jul 20

Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release

Jun 29

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Jun 15
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

May 11
Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Mar 08
Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest

Mar 07

Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?

Dec 17

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Dec 14
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment

Nov 20

Arbutus Biopharma: A First Assessment

Sep 15

We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Sep 11
We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment

Jun 29

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

May 21
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Bio slips 4% as Q1 revenue trails consensus

May 05

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:ABUS - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20269-84N/AN/A1
12/31/20256-73N/AN/A5
12/31/20247-74N/AN/A5
6/30/202410-77-73-73N/A
3/31/202413-74-79-78N/A
12/31/202318-73-87-86N/A
9/30/202322-75-87-86N/A
6/30/202324-73-84-83N/A
3/31/202333-70-84-83N/A
12/31/202239-69-36-35N/A
9/30/202236-69-38-38N/A
6/30/202233-76-36-35N/A
3/31/202221-85-30-29N/A
12/31/202111-88-68-68N/A
9/30/202110-87-64-63N/A
6/30/20218-84-60-59N/A
3/31/20218-79-54-54N/A
12/31/20207-76-52-51N/A
9/30/20206-83-50-50N/A
6/30/20208-147-61-61N/A
3/31/20207-156-70-70N/A
12/31/20196-165-72-71N/A
9/30/20196-158-75-75N/A
6/30/20195-100-65-64N/A
3/31/20195-73-65-64N/A
12/31/20186-67-69-68N/A
9/30/20187-83-62-61N/A
6/30/201812-68-65-64N/A
3/31/201812-86N/A-51N/A
12/31/201711-85N/A-49N/A
9/30/20178-267N/A-53N/A
6/30/20172-275N/A-52N/A
3/31/20171-387N/A-64N/A
12/31/20161-384N/A-58N/A
9/30/201614-171N/A-60N/A
6/30/201618-180N/A-47N/A
3/31/201621-65N/A-48N/A
12/31/201523-63N/A-56N/A
9/30/201517-62N/A-45N/A
6/30/201517-42N/A-49N/A
3/31/201515-33N/A-39N/A
12/31/201415-39N/A-12N/A
9/30/201418-35N/A-3N/A
6/30/201417-33N/A0N/A
3/31/201418-30N/A5N/A
12/31/201315-14N/A-7N/A
9/30/20131226N/A31N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ABUS devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ABUS devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ABUS devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ABUS ( 34% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ABUS ( 34% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ABUS devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y